KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elevance Health (ELV) Notes Payables (2016 - 2025)

Elevance Health (ELV) has disclosed Notes Payables for 16 consecutive years, with $180.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Notes Payables fell 50.0% to $180.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $180.0 million, a 50.0% decrease, with the full-year FY2024 number at $365.0 million, up 62.22% from a year prior.
  • Notes Payables was $180.0 million for Q3 2025 at Elevance Health, down from $360.0 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.6 billion in Q1 2024 to a low of $180.0 million in Q3 2025.
  • A 5-year average of $408.0 million and a median of $270.0 million in 2021 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: skyrocketed 62.22% in 2024, then tumbled 84.13% in 2025.
  • Elevance Health's Notes Payables stood at $275.0 million in 2021, then decreased by 3.64% to $265.0 million in 2022, then dropped by 15.09% to $225.0 million in 2023, then surged by 62.22% to $365.0 million in 2024, then plummeted by 50.68% to $180.0 million in 2025.
  • Per Business Quant, the three most recent readings for ELV's Notes Payables are $180.0 million (Q3 2025), $360.0 million (Q2 2025), and $250.0 million (Q1 2025).